Diabetic bone fragility through advanced glycation end product-collagen axis: Mechanisms and therapy of sodium glucose cotransporter 2 inhibitors

doi:10.4239/wjd.v16.i10.111813

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

(39)

(56)

(0)

(8)

(1330)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Diabetes. Oct 15, 2025; 16(10): 111813
Published online Oct 15, 2025. doi: 10.4239/wjd.v16.i10.111813

Table 3 Classification and representative structures of advanced glycation end-products

AGE type	Chemical name	Characteristics	Biological activity
CML	CML	One of the most common AGEs; formed via glycoxidation or lipid peroxidation	RAGE agonist; promotes inflammation and fibrosis
CEL	CEL	Structurally similar to CML; derived from pyruvate and other metabolic intermediates	Associated with insulin resistance
Pentosidine	Crosslink product of reducing sugars with lysine or arginine	Signature structure of AGE crosslinks	Strongly associated with bone fragility and arterial stiffness
MG-H1	MG-H1	Key biomarker of diabetes-related AGE	Promotes apoptosis and mitochondrial dysfunction

CML: Nepsilon-(carboxymethyl)lysine; CEL: Nepsilon-(carboxyethyl)lysine; MG-H1: Methylglyoxal-derived hydroimidazolone 1; AGE: Advanced glycation end product; RAGE: Receptor for advanced glycation end products.

Full Size Table

Citation: Li ZP, Luo C, Yu XM, Ye LY, Sun D, Duan CZ, Xu SY, Zeng MQ, Xu H, Peng ZY, Wang P, Wang YB, Ruan WJ, Xue ME, Zhang CJ, He DJ. Diabetic bone fragility through advanced glycation end product-collagen axis: Mechanisms and therapy of sodium glucose cotransporter 2 inhibitors. World J Diabetes 2025; 16(10): 111813
URL: https://www.wjgnet.com/1948-9358/full/v16/i10/111813.htm
DOI: https://dx.doi.org/10.4239/wjd.v16.i10.111813

Li ZP, Luo C, Yu XM, Ye LY, Sun D, Duan CZ, Xu SY, Zeng MQ, Xu H, Peng ZY, Wang P, Wang YB, Ruan WJ, Xue ME, Zhang CJ, He DJ. Diabetic bone fragility through advanced glycation end product-collagen axis: Mechanisms and therapy of sodium glucose cotransporter 2 inhibitors. World J Diabetes 2025; 16(10): 111813 [PMID: 41113476 DOI: 10.4239/wjd.v16.i10.111813]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.